An international team of researchers has broadened and deepened understanding of how inherited retinal dystrophies (IRDs) affect different populations of people and, in the process, have identified new gene variants that may cause the diseases.
An international team of scientists led by researchers at University of California San Diego School of Medicine employed an array of next-generation sequencing and gene-editing tools, such as CRISPR, to map the molecular dependencies – and thus vulnerabilities – of pancreatic cancer stem cells.
UC San Diego researchers report that individual immune response to SARS-CoV-2 may be limited by a set of variable genes that code for cell surface proteins essential for the adaptive immune system. The finding may help explain why COVID-19 immunity varies by individual.
After analyzing the genomes of more 250,000 military veterans, researchers have identified 18 specific, fixed positions on chromosomes that appear associated with post-traumatic stress disorder. The findings may point to new therapeutic drug targets.
UC San Diego School of Medicine researchers reported that genetic testing is cost-effective and beneficial for newly diagnosed patients with metastatic gastrointestinal stromal tumors (GIST), a rare type of cancer.
Scientists at University of California San Diego School of Medicine validated a more inclusive and comprehensive genetic tool, known as a polygenic hazard score (PHS), for predicting age of onset of aggressive prostate cancer.
The National Institutes of Health (NIH) has awarded researchers at University of California San Diego approximately $30 million over five years to expand and deepen longitudinal studies of the developing brain in children.
UC San Diego was awarded five COVID-19 Rapid Acceleration of Diagnostics (RADx) projects by the National Institutes of Health totaling nearly $33 million, which will fund efforts that range from managing a large data center to expanding testing in disadvantaged communities.
The NIH has launched a major clinical trial to assess the malaria drug hydroxychloroquine and antibiotic azithromycin as a treatment for COVID-19. The trial will recruit 2,000 participants at 30 sites. A Q&A with the trial’s team leader: Davey Smith, MD, of UC San Diego School of Medicine.
The Next Generation Precision Oncology Symposium, a novel meeting of industry and academic leaders in cancer science and medicine, will be held February 21, 2019 at UC San Diego Moores Cancer Center.
Health Media Contacts
Find the best contact for health-related media inquiries.
